Soligenix GAAP EPS of -$0.05 beats by $0.07 (SNGX:NASDAQ)

Soligenix reported Q3 GAAP EPS of -$0.05, exceeding estimates by $0.07. The company had $9.0 million in cash and cash equivalents as of September 30, 2026, according to its press release.

Original reporting
Published Nov 6, 2026, 12:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SNGX
Bullish
medium confidence
Mentioned
$SNGX
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$SNGXBullishLow
01

Why it matters

The earnings beat provides a small catalyst but does not materially shift the company's long‑term risk profile.

02

Market read

Micro‑cap earnings beat with modest cash position; limited broader market impact.

03

What to watch

Potential upcoming regulatory milestones or partnership news could change the outlook.

Relevance 6/10Novelty 6/10Timing: after-hours reaction

Background

Soligenix is a clinical‑stage biotech focused on rare diseases; its market cap is under $100M.

Company-level read

Ticker impact

$SNGXBullishMedium confidence
Context

Soligenix reported Q3 GAAP EPS of -$0.05, beating expectations by $0.07 and disclosed $9.0M cash on hand.

Expected impact

likely modest upward pressure as the market prices in the earnings beat

Evidence & confidence

The beat is small and the company is micro‑cap, so impact is limited but could attract short‑term buying.

Market effects

Minimal effect on the broader biotech sector.

Limited to U.S. micro‑cap investors.

None

Counterpoint

The beat may be outweighed by ongoing cash constraints and limited pipeline.

Key entities

  • Soligenix Inc.

    Biotech firm reporting Q3 earnings.

Related articles

$SNGXMedAI 8/10

Soligenix culls topical lymphoma asset after Phase III miss

Soligenix terminated the Phase III FLASH2 trial for its topical CTCL therapy HyBryte (SGX301/synthetic hypericin sodium) after interim analysis indicated it was unlikely to meet primary goals. The company will shift focus to dusquetide for Behçet’s disease and pursue commercial opportunities for its ThermoVax vaccine platform. The article also notes CTCL drug approvals and sales figures.

$SNGXMed

SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

Soligenix (Nasdaq: SNGX) reported no revenue for the quarter ended June 30, 2026. Net loss was $2.0 million, or ($0.12) per share, versus $2.7 million, or ($0.82) per share, a year earlier. The company said it discontinued its HyBryte (synthetic hypericin) Phase 3 FLASH2 program after a futility recommendation. Cash was about $9.8 million as of June 30, 2026.

$QTTBMedAI 9/10

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

$PANWHighAI 9/10

Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results

Palo Alto Networks Inc (PANW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Palo Alto Networks Reports Fiscal First Quarter 2027 Financial Results SANTA CLARA, Calif., Nov. 18, 2026 — Palo Alto Networks ® (NASDAQ: PANW), the global AI cybersecurity leader, announced today financial results for its fiscal first quarter ended October 31, 2026.

$IPARMedAI 8/10

INTERPARFUMS, INC. ANNOUNCES FULL YEAR 2027 GUIDANCE

INTERPARFUMS INC (IPAR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 FOR IMMEDIATE RELEASE INTERPARFUMS, INC. ANNOUNCES FULL YEAR 2027 GUIDANCE New York, New York, November 18, 2026, Interparfums, Inc. (NASDAQ GS: IPAR) (“Interparfums” or the “Company”) today announced initial guidance for its fiscal year ending December 31, 2027. In